Antithymocyte globulin (ATG)-based immunosuppression remains the standard immunosuppressive therapy (IST) for aplastic anemia (AA) patients lacking a sibling donor; however, treatment failures are relatively frequent, including about one-quarter to one-third of patients who do not show any response to initial IST, and about half of the initial responders who may experience subsequent relapses or require continuous maintenance IST. For these patients, there is the option of further IST, which may include additional courses of ATG-based IST, or attempts with alternative IST regimens. Alemtuzumab is a monoclonal anti-CD52 Ab, which has been recently investigated as novel IS agent for the treatment of AA patients. Recent data from different groups have clearly demonstrated the biological efficacy of Alemtuzumab in AA patients, ruling out the initial concerns about possible unacceptable infectious risks secondary to its extremely powerful lympholytic effect. Preliminary data demonstrate a remarkable efficacy, especially in the context of relapsed and, to less extent, refractory patients, whereas data in naïve patients are still limited. On the basis of these results, Alemtuzumab-based immunosuppression is a worthy option for AA and other marrow failure patients requiring a second-line IST. Here we describe a consensus regimen that the European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party suggests for AA patients failing initial IST who are not indicated for SCT.
INTRODUCTION

Acquired idiopathic aplastic anemia (AA)
1 is the most typical example of immune-mediated BM failure, as supported by a number of experimental observations. [2] [3] [4] Indeed, in the past three decades immunosuppressive therapy (IST) represented a key treatment strategy for AA patients, 5, 6 especially for patients lacking a sibling HLA-identical donor. Antithymocyte globulin (ATG) has been proven effective since the 1980s, remaining the key immunosuppressive agent up to date, in combination with CYA. 7, 8 Current standard IST for AA patients consists of ATG þ CYA, with an expected 60-70% probability of response and 70-80% OS at 1 year. 6, 9, 10 Both horse ATG preparations (ATGAM (Upjohn, Kalamazoo, MI, USA), 40 mg/kg per day for 4 days 11, 12 or Lymphoglobuline (Sanofi, Paris, France), 15 mg/kg per day for 5 days [13] [14] [15] ) seem equally effective for the treatment of AA; in contrast, rabbit ATG (Thymoglobulin (Sanofi), 3.5 mg/kg per day for 5 days) has been shown inferior to horse ATG in a large randomized study, 16 as well in a pilot study from the Severe Aplastic Anemia Working Party (SAAWP). 17 Thus, horse ATG þ CYA remains the preferred first-line IST for AA patients not eligible for a SCT from a sibling HLA-matched donor. According to the most recent studies, [18] [19] [20] a substantial proportion of AA patients (30-40%) do not respond to initial IST; in addition, at least onethird of responders may relapse of their disease or floating with mild-to-moderate cytopenia(s), which requires chronic maintenance IST by CYA. All these patients need a second-line treatment.
SALVAGE IMMUNOSUPPRESSIVE TREATMENT FOR AA
SCT is the most appropriate second-line treatment for the majority of AA patients failing first-line IST; however, given that it is conceivable that such failures may also be due to inadequate IST (especially for patients relapsing after an initial response), 21 further IST represents a worthy option for patients lacking a well-matched donor or lacking a low-risk transplant procedure. Indeed, a second course of ATG-based IST is often given to relapsed or refractory AA patients, with relevant response rates. Response rates are remarkable (50-80%), especially in patients relapsing after a good hematological response, whereas patients refractory after the first ATG have low chance (20-30%) to respond to further courses, with response rates substantially varying among published reports. [22] [23] [24] [25] In this context, rabbit ATG is often preferred to horse ATG, to decrease the risk of serum sickness and other side effects secondary to previous sensitization to horse proteins. However, ATG-based IST remains a burdensome treatment and, given that subsequent relapses are possible, there is a room for investigating alternative IST regimens in relapsed/refractory AA patients, aiming to reduce the toxicity of the standard IST regimens, possibly retaining (or even improving) their efficacy.
ALTERNATIVE IMMUNOSUPPRESSIVE REGIMENS FOR AA
On the basis of the observation that further IST may rescue patients failing initial ATG þ CYA, one may argue that standard IST regimens are not sufficient to control the immune processes underlying AA, at least in a fraction of AA patients. Thus, many groups attempted different strategies to intensify the immunosuppression delivered with standard ATG þ CYA by adding a third immunosuppressive agent. Unfortunately, to date all these efforts were unfruitful. Indeed, the addition of the purine synthesis inhibitor mycophenolate mofetil did not lead to improved response or decreased relapse rate in a prospective study. 26 Similarly, in a prospective randomized study the mammalian target of rapamycin inhibitor rapamycin (sirolimus) did not result in any advantage in terms of hematological response in comparison to the control arm (ATG þ CYA), with overlapping survival rates. 18 An alternative strategy for improving the standard IST regimen was based on the delivery of lymphotoxicity by using antilymphocyte agents other than ATG. The best known approach was initially developed at the Johns Hopkins Hospital (Baltimore, MD, USA), where investigators tested cyclophosphamide at the dose of 50 mg/kg intravenously on 4 consecutive days (without stem cell support), showing a response rate of about 70%. 27 Even if a prospective randomized study comparing ATG þ CYA with cyclophosphamide was prematurely stopped because of increased infectious complications possibly secondary to the prolonged neutropenia due to a direct myelotoxicity of cyclophosphamide, 28 ,29 the on-going single-center experience at John Hopkins continues to show excellent results. Indeed, in a recent update on 67 SAA patients, the response rate was 70.5% in naïve patients and 47.8% in refractory patients, with acceptable early toxicity (incidence of fungal infections were 18.2 and 43.5% in naïve and refractory patients, with 7.5% early mortality) and excellent long-term survival (10-year survival and of treatmentfailure-free survival were 88 and 58% in naïve patients, and 61.8 and 27.7% in refractory patients). 30 
ALEMTUZUMAB-BASED IMMUNOSUPPRESSION: THE STATUS OF ART
Alemtuzumab-based IST: the rationale Alemtuzumab (Campath 1H; Mabcampath (Sanofi)) is a fully humanized anti-CD52 MoAb, which kills all CD52 bearing cells via both Ab-dependent cellular cytotoxicity and C 0 -mediated lysis. 31 Given that CD52 is widely present on all human lymphocytes, expressed on the surface membrane via a glycosyl-phosphatidylinositol anchor, but not on hematopoietic stem cells or committed hematopoietic progenitors, Alemtuzumab is an excellent agent, which may deliver a lympholytic effect while sparing hematopoietic cells. Alemtuzumab was initially investigated in lymphoid malignancies, where it showed an excellent lympholytic effect; in fact, in 2001 it has been approved as second-line treatment for CLL. Subsequently, it has been used as salvage treatment in other lymphoproliferative disorders (including large granular lymphocyte leukemias); 32 more recently, its powerful immunosuppressive effect has been successfully tested in an autoimmune disorder such as multiple sclerosis. 33 Notably, Alemtuzumab was also utilized as in vivo depleting agent in the context of SCT; the most utilized schedule consists of a total dose of 100 mg, administered over 5 days as 20 mg i.v. infusions, which led to remarkable immune-ablation comparable to that observed after ATG. [34] [35] [36] The pharmacokinetics of Alemtuzumab have not been fully elucidated in any specific hematological disorder; however, one may anticipate that pharmacokinetics and biodistribution of Alemtuzumab should be dominated by available binding sites, which differ between lymphoid malignancies with massive lymphocytosis and other conditions. Outside the context of lymphocytosis and lymphoproliferative disorders, it has been estimated that there are approximately 10 12 lymphocytes in a healthy adult, each one harboring about 5 Â 10 5 CD52 molecules; thus, about 100 mg of Alemtuzumab are needed to saturate all binding sites. 37 Indeed, theoretical calculations indicate that a dose of 100 mg of Alemtuzumab should deliver a complete lymphocyte depletion, as confirmed by the fully and long-lasting immunoablation observed in vivo after Alemtuzumab-based conditioning regimens preparative to SCT. Even if initially developed for i.v. utilization, Alemtuzumab is now commonly administered as s.c. injections. Indeed, a pharmacokinetic study comparing the two administration routes in refractory CLL patients showed that concentration peaks achieved after s.c. and i.v. administration were comparable, even if in the former it may take longer to reach the steady state. 38 On the basis of all these assumptions, Alemtuzumab seems an ideal IS agents for the treatment of AA and other immune-mediated BM failures.
Alemtuzumab-based IST in AA: the SAAWP experience Starting in 2004, in collaboration with the European Group for Blood and Marrow Transplantation SAAWP, we have conducted a phase II study investigating Alemtuzumab þ low-dose CYA for the treatment of AA and related immune-mediated BM failures (NCT00895739). 39 Alemtuzumab was administered s.c. at doses of 3-10-30-30-30 on 5 consecutive days (total dose 103 or 73 mg in patients with moderate AA); low-dose CYA (1 mg/kg) was given from day 7. The dose was chosen based on concurrent regimens utilized for immune-mediated cytopenia 40 and for pre-transplant immunoablation;
34-36 the s.c. administration route was preferred over i.v. according to proven equality. 38 Premedication included i.v. steroids, antihistamines and oral paracetamol. A strict antiinfectious policy was observed in all patients, which included broad anti-bacterial and anti-fungal agents (ciprofloxacin and itraconazole, respectively) in case of severe neutropenia (o500/mL), specific anti-CMV prophylaxis (valganciclovir 450 mg orally bi-daily for 3 months, followed by CMV DNAemia monitoring and pre-emptive treatment) and pneumocystis prophylaxis (cotrimoxazole bi-daily thrice a week). 41 We enrolled 13 AA patients, of whom 9 had no previous IST; all the patients completed the treatment without any relevant adverse event, usually in an outpatient regimen (the treatment itself did not require hospitalization in any case). The most frequent adverse events were mild infusion reactions (local rubor, chills and fever), usually selflimiting or easily managed by paracetamol. All patients showed complete lymphocyte depletion within 2-3 days, with lymphocyte count below 0.1 Â 10 3 /mL. The kinetics of immune reconstitution was very slow in all patients, especially for the CD4 þ compartment; median lymphocyte count was about 0.5 and 0.85 Â 10 3 /mL at 6 and 12 months, respectively. The lymphocyte subsets faster to repopulate were natural killer and B cells, followed by CD8 þ T cells (which were about 0.1 and 0.2 Â 10 3 /mL at 6 and 12 months); in contrast, CD4 þ lymphocytopenia lasted several months after treatment (about 0.1 and 0.2 Â 10 3 /mL at 6 and 12 months). Irrespective of the profound and long-lasting lymphopenia, infectious complications were not a major concern in our study. In fact, early infectious mortality was in the expected range (one sepsis and one pneumonitis, both in elderly patients with very severe neutropenia); the long-term follow-up of the study confirmed the excellent safety profile. 42 When all the 28 patients enrolled in the study were considered (13 AA, 13 pure red cell aplasia (PRCA) and 2 pure white cell aplasia (PWCA), see below), after a cumulative observation of 978 patient-months infectious events were infrequent, and mostly included viral reactivation: 1 Varicella zoster with shingles, 4 herpes simplex and 4 subclinical CMV reactivation (as assessed by a sensitive PCR method, in patients who have discontinued the prophylactic ganciclovir), all resolving quickly after anti-viral treatment (either acyclovir or preemptive valganciclovir). 41 No CMV disease, EBV-related disease or lymphoproliferative disorder was observed. To note, a subclinical (no increase of liver enzymes) seroconversion of HBV with DNAemia was seen in a patient with occult HBV infection (HBsAg À /HBcAb IgG þ ), with prompt viral clearing after lamivudine treatment (three subsequent patients with possible occult HBV infection received prophylactic lamivudine, without subsequent HBV viral reactivation). The only exception to this safe profile was a patient with a metastatic thymic carcinoma and concomitant PRCA who, several months after Alemtuzumab and during salvage chemotherapy for her cancer, developed a fatal progressive multifocal leucoencephalopathy (with detection of JC virus in the cerebrospinal fluid). Non-infectious adverse events were rare, and included mild increase of liver enzymes in four patients and of serum uric acid in two patients, which were transient in all cases. In addition, in patients with partially preserved blood cell counts at baseline (these data are mostly drawn from patient with single-lineage cytopenia), transient worsening of blood counts was observed, 43 usually between 2 and 6 weeks after treatment (possibly managed by on demand G-CSF). In contrast with some precedent observation, [44] [45] [46] Alemtuzumab treatment did not result in the emergence of PNH clones, even if (likely pre-existing) CD52 À lymphocyte may become evident in the early post-treatment period (and then diluted at the time of lymphocyte rise).
In all, 9 of the 13 patients (69%) showed a hematological response (cumulative probability of response was 78% at 12 months), with 5 CRs (38%) and 4 PRs (31%); hematological improvement was initially seen at 3 months, even if most cases achieved their best response after 6 months. Patients receiving Alemtuzumab as first-line treatment seem to have a higher chance to respond: out of 9 patients, 3 had a CR and 2 a very good PR. Indeed, the initial efficacy of Alemtuzumab as an IST regimen was impressive; however, irrespective of the persistent severe lymphocytopenia, relapses were frequent, despite chronic CYA maintenance treatment (even if at a very low dose). In fact, seven out of nine patients experienced a relapse; however, re-treatment by further Alemtuzumab (even administered as single 30 mg dose in case of early relapses) again achieved a hematological response. Late failures included two refractory relapses (out of the nine responding patients; 22%) and two clonal evolutions (out of 13 patients, 15%; both myelodysplastic syndromes carrying abnormalities of chromosome 7). The 4-year failure-free survival and OS were 37% and 67%, respectively. These promising data of the prospective trial were only partially confirmed in a retrospective survey conducted among the centers of the European Group for Blood and Marrow Transplantation SAAWP. Among the eight patients included, only three showed a partial hematological response. However, it has to be emphasized that all these patients were heavily pretreated, having failed multiple lines of IST, consistent with the assumption that IS-refractory cases are unlikely to be cured by further intensification of IST. 39 Alemtuzumab-based IST: other experiences Investigators at the National Institutes of Health has extensively investigated Alemtuzumab as novel IST regimen in patients suffering from AA; 47 Alemtuzumab was given as 10 mg i.v. injections, in 10 consecutive days (total dose 100 mg), in a CYAfree regimen. Patients were relapsed (n ¼ 25) or refractory (n ¼ 27) after a previous ATG-based IST course, or even naïve from any IST (n ¼ 16). In agreement with the findings of the SAAWP experience, the regimen was feasible and well tolerated, without any increase in infectious morbidity or mortality (in contrast to that seen after cyclophosphamide). Viral reactivation (both EBV and CMV) was seen after Alemtuzumab, in all cases without any clinical consequence; 48 to note, in contrast to our aggressive anti-viral policy, no patient has received any prophylactic or pre-emptive anti-viral treatment, without experiencing any symptomatic infection. The hematological response, as expected, was quite heterogeneous according to the phase of disease. In fact, relapsed patients showed an excellent response rate of 56%, with 86% 3-year survival, whereas in refractory patients' response and 3-year survival rates were 37% and 83%, respectively. Quite surprisingly, these promising results as second-line treatment were balanced by the disappointing data from the 16 naive patients, who showed only a 19% response rate, which led to the premature stop of this trial. 47 The biological efficacy of Alemtuzumab in AA is also confirmed by two other studies from Korea and Mexico. The Korean study 49 was designed with a dose-escalating regimen, which investigated a low (60 mg) and a high (90 mg) dose of Alemtuzumab (delivered in 3 consecutive days), in combination with CYA as maintenance IST. On the 17 patients enrolled, the overall response rate was 35% (23% CR and 12% PR), with a 2-year survival of 81%. Quite surprisingly, all responses were observed in the low-dose (60 mg) cohort, whereas no patients receiving 90 mg responded; this study did not raise any safety concern. A similar low dose was investigated in the Mexican study, 50 which included 14 untreated AA patients receiving s.c. Alemtuzumab at the dose of 50 mg (10 mg in 5 consecutive days), in combination with longterm CYA (2 mg/kg twice a day). With a median follow-up of 20 months, the response rate was 57%, with 14% complete and 43% partial responses; median time to response was 2.5 months, whereas median time to transfusion independence was 4.5 months. Even in this study the safety profile was excellent, with no treatment-related infectious mortality and no CMV reactivation (here a broad anti-viral prophylaxis with acyclovir was utilized). These excellent results were confirmed in the long-term follow-up, which showed no patient relapsing or developing late clonal evolution; the OS was 71% at 38 months, with deaths due to hemorrhages or infectious complication in non-responding patients.
Alemtuzumab-based IST in lineage-restricted BM failures AA is the paradigm of immune-mediated BM failures, and typically includes the involvement of all blood lineages. More rarely, cytopenias may arise from marrow failures restricted to a single hematopoietic lineage: PRCA, PWCA and acquired amegakaryocytic thrombocytopenia. These disorders are often associated with other diseases (for example, thymoma or autoimmune diseases), which may share (or even be the cause of) an underlying immunemediated pathogenic mechanism. According to the established theory, here the targets in the hematopoietic hierarchy are lineage-committed hematopoietic progenitors rather than multipotent HSCs (as for AA). 51 Thus, even for single-lineage marrow failures, IST is a reasonable treatment option; unfortunately, only small case series or anecdotal cases are reported, mostly employing mild IST based on steroids and/or CYA. 51 In some cases, more intensive IST may be required, and Alemtuzumab has been proven effective in small series. 52, 53 Our prospective trial also included patients suffering from lineage-restricted marrow failures, such as PRCA and PWCA; the scheduled dose was lower compared with that delivered to AA patients (3-10-30-30 in 4 consecutive days, 73 mg total dose). 39, 42 In all, 13 PRCA (nine untreated) and two PWCA (one untreated) patients were enrolled; PRCA was often associated with other diseases, such as thymoma or connective tissue disorders, whereas one PWCA patient harbored a large granular lymphocyte population. The response rate was excellent, with an overall response rate of 84% for PRCA (eight CRs and three PRs) and of 100% for PWCA (two out of two complete responders). One of the two nonresponding PRCA revealed to have a non-immune-mediated disease (she quickly developed a myeloproliferative disorder). In comparison to AA, responses were faster, likely due to the downstream target in the hematopoietic hierarchy; however, even relapses were earlier, affecting five of the eight PRCA and one of the two PWCA, regardless of maintenance CYA. Despite the excellent safety profile described above, the long-term outcome of PRCA patients was quite disappointing, because of refractory relapses (18%), clonal evolution (30%, myelodysplastic syndromes with two cases of 5q À abnormalities, two megakaryoblastic leukemias) or progression of concomitant disease (autoimmune or thymomas). For PRCA patients, 3-year failure-free survival and OS were only 45% and 54%, respectively. In contrast, both PWCA patients showed an excellent long-term outcome, being both alive in remission. 39, 42 Alemtuzumab and low-dose CYA as alternative immunosuppression: a consensus regimen In consideration of the data described above, the SAAWP has reached a consensus on an alternative Alemtuzumab-based IST, which is suggested for patients needing a salvage immunosuppression. The suggested regimen is identical to that reported previously, and included s. Routine evaluation of AA and other marrow failure patients should follow standard guidelines, to exclude any inherited or acquired disorder accounting for the BM failure (namely Fanconi anemia, dyskeratosis congenita and other inherited marrow failures, and all forms of acquired myelodysplastic syndromes). The presence of a PNH clone is not an exclusion criterion.
Investigational treatment Patients will receive Alemtuzumab (MabCampath) for 5 days, starting with a dose of 3 mg on day 1, followed by 10 mg on day 2 and 30 mg on days 3 and 4 (and 5, only for SAA patients). The drug is available as 30 mg vials. It will be administered as s.c. injections. As prevention of Alemtuzumab-related side effects, including first dose reaction, 30 min before Alemtuzumab, a premedication will be administered, which includes steroids, an anti-histamine and paracetamol. Patients suffering from single-lineage marrow failure will receive only 73 mg of Alemtuzumab (3, 10, 30 and 30 mg in 4 consecutive days).
Concomitant treatments
The patients will also receive oral CYA, starting on day 7 at the dose of 1 mg/kg, and then adjusted on blood levels for at least 180 days, and then tapered according to clinical conditions. Anti-infectious prophylactic measures will be adopted to prevent opportunistic infections according to institutional policy, possibly in agreement with supportive care guidelines. Anti-bacterial and anti-fungal prophylaxis will be administered to all patients with ANC o500/mL. Anti-pneumocystis prophylaxis is recommended with cotrimoxazole as long as CD4 þ lymphocytes o0.2 Â 10 3 /mL or for at least 6 months after Alemtuzumab. Anti-CMV prophylaxis is not warranted, even if CMV monitoring and possible pre-emptive treatment is recommended for at least 6 months after Alemtuzumab treatment (especially in seropositive patients). In patients with possible occult HBV, lamivudine prophylaxis should be considered. Additional supportive therapies (including blood cell component transfusions) will be administered according to standard practice, as well as any additional medication needed as a result of concomitant morbidities. Irradiated blood products (425 Gy) should be used. A strict clinical and laboratory evaluation is recommended for at least 24 months after treatment starting.
CONCLUSIONS
Alemtuzumab-based immunosuppression has been successfully investigated in recent years as an alternative IST regimen for patients suffering from AA and other immune-mediated marrow failure. Available data support the notion that Alemtuzumab is relatively easy to administer, with an acceptable safety profile, which has ruled out the initial concerns about the risk of possible infectious complications. Efficacy data demonstrate the biological efficacy of Alemtuzumab as an immunosuppressive agent in this context, even if the actual response rate has to be investigated in larger series, and likely varies according to the disease phase. In recent studies, Alemtuzumab has been used: (1) in different patient subsets; (2) by different administration routes; (3) at different doses; (4) in different associations with other IS agents (as maintenance therapy). Thus, a common regimen may help to understand the role of Alemtuzumab in the context of IST for AA, possibly aiming to refine the best Alemtuzumab-based IST to be utilized in the future for specific subsets of patients suffering from immune-mediated marrow failures.
